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PROTECTION AGAINST ISCHEMIA AND 
REPERFUSION INJURY 
This application is a continuation of US. patent applica 
tion Ser. No. 09/947,656, ?led Sep. 6, 2001 now US. Pat. 5 
No. 6,900,178, Which claims bene?t of Application Ser. No. 
60/232,093, ?led Sep. 12, 2000. 
FIELD OF THE INVENTION 
The invention relates to compounds protective against 
ischemia and reperfusion injury, particularly in the myocar 
dium, and their use. 
BACKGROUND 
Tissues deprived of blood and oxygen undergo ischemic 
necrosis or infarction With possible irreversible organ dam 
age. In some circumstances, hoWever, such as during cardiac 
surgery, it is desirable to interrupt the normal myocardial 
contractions (cardioplegia) and actually induce ischemia. 
Such elective or obligatory ischemia occurs in the presence 
of safeguards such as cardioplegia-induced cardiac arrest 
and hypothermia. While these safeguards provide consider 
able myocardial protection, alteration of myocardial ener 
getics (stunning) and poor postoperative ventricular function 
still remain signi?cant problems. 
Once the How of blood and oxygen is restored to the organ 
or tissue (reperfusion), the organ does not immediately 
return to the normal preischemic state. Reperfused postis 
chemic non-necrotic myocardium is poorly contractile and 
has reduced concentrations of high energy nucleotides, 
depressed subcellular organelle function and membrane 
damage that resolves only sloWly. Although reperfusion 
restores oxygen and reverses ischemia, repletion of high 
energy nucleotides such as adenosine triphosphate (ATP) 
and reversal of ischemic membrane damage is sloW, and 
contractile function may be profoundly depressed for a long 
period. Just minutes of ischemia causes loss of myocardial 
systolic Wall thickening for hours. Longer periods of revers 
ible ischemia may depress contractility for days. Studies 
con?rm that, despite restoration of myocardial How and a 
quick recovery of myocardial oxygen consumption (MV02) 
folloWing ischemia, there is only very sloW recovery of 
myocardial contractile function. The problems are exacer- 45 
bated in high risk patients, such as those With poor preop 
erative ventricular function, recent myocardial infarction or 
left ventricular hypertrophy. These same problems also 
occur during organ storage for cardiac transplant, under 
Which there are time constraints due to the limits of myo- 50 
cardial preservation. 
Postischemic dysfunction may be due to a variety of 
factors. Oxygen free radicals may play a role, as generation 
of free radicals in stunned myocardium has been demon 
strated and free radical scavengers have been shoWn to 55 
attenuate contractile dysfunction. Impaired intracellular cal 
cium handling and calcium overload during early reperfu 
sion may contribute to postischemic dysfunction; While 
calcium infusions enhance contractility in both normal and 
postischemic myocardium, ischemia as short as a feW min- 60 
utes produces an impairment in sarcoplasmic reticulum 
calcium transport and a shift of the calcium ATPase activity. 
Postischemic myocardium is also associated With reduced 
concentrations of myocardial high-energy phosphates and 
adenine nucleotides, as obligatory reduction in myocardial 65 
ATP content during ischemia occurs as myocytes utiliZe ATP 
for maintenance of cellular integrity. Since ATP is essential 
20 
25 
30 
40 
2 
for myocardial contraction and relaxation, ATP depletion 
may have detrimental effects upon postischemic myocardial 
functional recovery. 
The high volume of cardiac-related surgeries, both elec 
tive and emergency procedures and including cardiac trans 
plants, lead to the above-described problems. Thus, methods 
and agents to provide protection against myocardial 
ischemia and to avoid post ischemic dysfunction are needed. 
SUMMARY OF THE INVENTION 
The invention is directed to agents and a method of using 
the agents to reduce the injury associated With ischemia and 
reperfusion of organs such as the heart. The compounds are 
Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 SEQ ID N011, 
hereinafter referred to as Deltorphin A, and Tyr-D-Ala-Phe 
Gly-Tyr-Pro-Ser-Gly-Glu-Ala-Lys-Lys-Ile SEQ ID N012, 
hereinafter referred to as Dermorphin H. Administration of 
Deltorphin A SEQ ID N011 and Dermorphin H SEQ ID 
N012, particularly prior to an ischemic event, reduces tissue 
necrosis and preserves organ function. 
In one embodiment, a method of protecting against 
ischemia and reperfusion injury in a mammal is disclosed. 
An effective concentration of DeltorphinA SEQ ID N011 or 
Dermorphin H SEQ ID N012 is administered to the mammal 
in a pharmaceutically acceptable formulation prior to the 
onset of ischemia, for example, 24 hours prior to ischemia. 
In other embodiments, Deltorphin A SEQ ID N011 or 
Dermorphin H SEQ ID N012 is administered substantially 
concurrently With the onset of ischemia, during an ischemic 
episode, or post-ischemia. The formulation may be admin 
istered parenterally at a concentration in the range of about 
1*20 mg/kg of body Weight. 
The invention is also directed to a method to prevent 
damage to an isolated organ, for example, a heart for 
transplant. The isolated organ is exposed to a preservative 
solution containing an effective amount of Deltorphin A 
SEQ ID N011 or Dermorphin H SEQ ID N012. The con 
centration of Deltorphin A SEQ ID N011 or Dermorphin H 
SEQ ID N012 in the preservative solution for a heart is about 
100 uM. 
The invention is additionally directed to a method for 
reducing effects of an ischemic episode in a mammal by 
administering an effective concentration of Deltorphin A 
SEQ ID N011 or Dermorphin H SEQ ID N012 in a phar 
maceutically acceptable carrier. Administration is prior to or 
substantially concurrently With the onset of ischemia, or one 
hour post cerebral ischemia. 
The invention is further directed to a composition that 
protects a mammalian organ from injury. The composition 
contains Deltorphin A SEQ ID N011 or Dermorphin H SEQ 
ID N012, in either a naturally occurring form or a synthe 
siZed form. 
The invention is also directed to an organ preservative 
solution that contains Deltorphin A SEQ ID N011 or Der 
morphin H SEQ ID N012 at a concentration effective to 
protect the organ, such as a heart, from ischemic injury. 
These and other advantages of the invention Will be 
apparent in light of the folloWing draWings and detailed 
description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a histogram shoWing myocardial infarction siZe 
in control and treated animals. 
FIG. 2 is a histogram shoWing post-ischemic release of 
troponin I in control and treated animals. 
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FIG. 3 is a graph showing end diastolic pressure in the left 
ventricle of control and treated animals. 
FIG. 4 is a graph showing functional recovery in control 
and treated animals. 
FIG. 5 is a histogram shoWing ventricular functional 
recovery in control and treated animals. 
DETAILED DESCRIPTION 
The invention is directed to compounds that have a 
salutary effect on cardiac function folloWing ischemia, and 
methods of using the compounds. The compounds may be 
administered directly to an individual, and are particularly 
effective When administered 24 h prior to the onset of 
ischemia. This may occur, for example, prior to scheduled 
cardiac surgery. The compounds may also be included in a 
preservative solution for an isolated organ, such as a heart or 
liver being maintained viable for transplant. 
One of the compounds is a heptapeptide having the 
sequence Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 SEQ ID 
N011, hereinafter referred to as deltorphin A. Another of the 
compounds is a thirteen amino acid sequence Tyr-D-Ala 
Phe-Gly-Tyr-Pro-Ser-Gly-Glu-Ala-Lys-Lys-Ile SEQ ID 
N012. The peptides may be produced by a number of 
methods, such as using an automated peptide synthesiZer, 
through recombinant molecular techniques, or isolated from 
a naturally occurring source, as is knoWn to one skilled in the 
art. Deltorphin A SEQ ID N011 has a molecular Weight of 
955.1 daltons, and Dermorphin H SEQ ID N012 has a 
molecular Weight of about 1430.64 daltons. Both Deltorphin 
A SEQ ID N011 and Dermorphin H SEQ ID N012 are 
insoluble in Water or saline, but may be solubiliZed by 
adding 100 uM of a solution comprised of ethanol, propy 
lene glycol, and 1 N NaOH in a 11111 ratio, With sterile 
physiological saline then used to obtain the appropriate 
concentration. The initial alkaline pH is adjusted to 7.4 With 
1 N HCl. 
Deltorphin A SEQ ID N011 and Dermorphin H SEQ ID 
N012 that have been solubiliZed may be administered by 
parenteral means, for example, by intravenous injection. In 
one embodiment, administration of Deltorphin A SEQ ID 
N011 is at the time of induced ischemia, but may also be 
added during or even after an ischemic event. For admin 
istration into a mammal, a dose of about 1420 milligrams per 
kilogram (mg/kg) is useful. For administration into a tissue 
or organ preservation solution, a concentration of about 100 
uM is useful. 
Deltorphin A SEQ ID N011 and Dermorphin H SEQ ID 
N012 may be administered directly into a mammal, either 
alone or in combination With other substances. Alternatively, 
it may be added as a component of a solution used to 
maintain the viability of isolated organs, such as an additive 
to cardioplegia and other organ preservation solutions. In 
one embodiment, Deltorphin A SEQ ID N011 and/or Der 
morphin H SEQ ID N012 is coadministered as an adjuvant 
With other compounds or strategies that are designed to 
protect organs from ischemia. As an example, Deltorphin A 
SEQ ID N011 and/or Dermorphin H SEQ ID N012 may be 
administered With agents that affect nitric oxide (N0) syn 
thase, such as arginine hydrochloride. Arginine hydrochlo 
ride is knoWn to prevent the decline in cardiac function 
folloWing an ischemic episode. 
The folloWing description demonstrates use and ef?cacy 
of Deltorphin A SEQ ID N011 and Dermorphin H SEQ ID 
N012 in a variety of systems. 
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Perfused Heart 
Deltorphin A SEQ ID N011 or Dermorphin H SEQ ID 
N012, at a dose of 2 mg/kg and solubiliZed as described 
above, Was administered by tail vein injection into rats 
Weighing betWeen about 350400 g (number of animals 
(n):6). Control rats (n:6) Were injected in the same manner 
With an equal volume of 0.9% NaCl. After 24 h, the hearts 
from both treated and control animals Were excised and 
perfused in a modi?ed Langendorlf perfusion apparatus at 
37° C. using oxygenated Krebs-Henseleit buffer as the 
perfusate, as knoWn to one skilled in the art. Coronary 
perfusion pressure Was maintained at 700 mm Hg by regu 
lating coronary ?oW. All hearts Were paced at 5.5 HZ (300 
beats per minute, bpm) except during ischemia. A saline 
?lled balloon Was inserted in the left ventricle to measure 
developed pressure (DP) and end-diastolic pressure (EDP) 
in mm Hg. After 15 min equilibration, both groups Were 
subjected to 20 min Zero-?ow global ischemia, and then 
Were reperfused for 120 min. 
Left ventricles Were isolated and divided into three seg 
ments along their short axis, stained With triphenyltetraZo 
lium chloride, and stored in formalin. Infarct siZe Was 
measured on digitiZed images and expressed as a percentage 
of myocardium. Data Were expressed as mean plus or minus 
standard error of the mean (:SEM) and Were analyZed using 
a paired Student’s t-Test. Con?dence limits Were established 
at 95%. 
The results are shoWn in FIG. 1, Which is a histogram of 
the infarct siZe in hearts from animals receiving only saline 
(control, solid bar), in animals treated With Deltorphin A 
SEQ ID N011 at 2.0 mg/kg (treated, open bar) 24 h prior to 
20 min ischemia and 120 min reperfusion, and animals 
treated With Dermorphin H SEQ ID N012 at 2.0 mg/kg 
(treated, hatched bar) 24 h prior to 20 min ischemia and 120 
min reperfusion. Pretreatment of animals With Deltorphin A 
SEQ ID N011 or Dermorphin H SEQ ID N012 decreased the 
percent of infarct siZe. Control rats had a mean infarct siZe 
of 27:5%, While rats pretreated With Deltorphin A SEQ ID 
N011 had a reduced mean infarct siZe of 12.95:3.3%, and 
rats pretreated With Dermorphin H SEQ ID N012 had a 
reduced mean infarct siZe of 13.5:3.5%. 
Speci?c infarct volumes in four separate cross sectional 
areas of brains isolated from animals treated post-ischemia 
With DeltorphinA SEQ ID N011 and Dermorphin H SEQ ID 
N012 are shoWn in Tables 143. In each case, six male mice 
(strain C57) Were subjected to ischemia for one hour and 
then received an injection of either 100 pl normal saline 
(vehicle), 100 pl of 4.0 mg/kg Deltorphin A SEQ ID N011 
(Table 2), or 100 pl of 4.0 mg/kg Dermorphin H SEQ ID 
N012 (Table 3). The dose of DeltorphinA SEQ ID N011 and 
Dermorphin H SEQ ID N012 may be in the range of 1 mg/kg 
to 4 mg/kg. Reperfusion folloWed for 24 hours, then animals 
Were sacri?ced and 2 mm brain sections from each of four 
areas Were evaluated. The total cross section area is the sum 
of the four cross section areas; likeWise, the total damaged 
cross section areas is the sum of the four damaged cross 
section areas for each animal. 
US 7,060,792 B2 
5 
TABLE 1 
Saline (Vehicle) Treated 
Cross 14.81 14.65 12.55 13.18 15.35 15.9 
Section 
Area 1 
Cross 
Section 
Area 2 
Cross 
Section 
Area 3 
Cross 
Section 
Area 4 
22.52 22.39 19.52 20.68 22.08 20.22 
25.24 25.45 21.84 23.51 24.77 22.69 
24.51 24.05 21.54 24.98 23.81 22.73 
Total 86.54 75.45 82.35 86.01 81.54 
Cross 
Section 
Area 
Damaged 
Cross 
Section 
Area 1 
Damaged 
Cross 
Section 
Area 2 
Damaged 
Cross 
Section 
Area 3 
Damaged 
Cross 
Section 
Area 4 
87.08 
6.58 4.49 5.77 5.02 4.83 5.86 
9.7 6.86 7.42 8.21 8.81 6.57 
11.86 10.65 11.79 
10.02 12.22 11.03 11.21 10.26 10.76 
Total 34.27 34.87 36.23 33.42 31.43 
Damaged 
Cross 
Section 
Area 
Damaged % 
Corrected 
Volume 
38.16 
43.82 
87.644 
39.60 
68.54 
46.22 
69.74 
44.00 
72.46 
38.86 
66.84 
38.55 
62.86 
For animals receiving only saline after one hour of 
ischemia, the infarct volume Was about 42% (total damaged 
cross section area of 208.38, total cross section area of 
498.97, 208.38/498.97:0.417). The corrected volume Was 
obtained by multiplying the damaged cross section area by 
2, since 2 mm sections Were assessed. In all six control 
animal this Was 428.08, yielding an average infarct volume 
of 71.35 mm3 (428.08/6), With a standard deviation of 
18.598. 
TABLE 2 
Deltorphin A Treated 
Cross 16.42 15 13.89 14.67 15.23 14.56 
Section 
Area 1 
Cross 22.07 22.81 20.06 21.23 20.78 21.34 
Section 
Area 2 
Cross 24.17 25.51 23.52 23.79 24.14 24.56 
Section 
Area 3 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
6 
TABLE 2-continued 
Deltorphin A Treated 
Cross 20.77 23.49 23.24 21.55 22.34 20.98 
Section 
Area 4 
Total 
Cross 
Section 
Area 
Damaged 
Cross 
Section 
Area 1 
Damaged 
Cross 
Section 
Area 2 
Damaged 
Cross 
Section 
Area 3 
Damaged 
Cross 
Section 
Area 4 
83.43 86.81 80.71 81.24 82.49 
4.14 4.98 
7.48 7.7 
3.69 3.26 9.49 8.59 9.23 8.75 
3.77 3.4 7.36 6.74 6.94 7.11 
Total 
Damaged 
Cross 
Section 
Area 
Damaged % 
Corrected 
Volume 
20.1 16.66 29.64 27.28 28.85 27.45 
24.09 
40.2 
19.19 
33.32 
36.72 
59.28 
33.58 
54.56 
34.97 
57.7 
33.71 
54.9 
For animals receiving Deltorphin A after one hour of 
ischemia, the infarct volume Was reduced to about 30% 
(total damaged cross section area of 149.98, total cross 
section are of 496.12, 149.98/496.12:0.302). In all six 
Deltorphin A treated animals, the corrected volume Was 
299.96, yielding an infarct volume of49.99 mm3 (299.96/6), 
With a standard deviation of 110.63. 
TABLE 3 
Dermorphin H Treated 
Cross 14.92 13.87 14.94 14.65 13.69 14.27 
Section 
Area 1 
Cross 
Section 
Area 2 
Cross 
Section 
Area 3 
Cross 
Section 
Area 4 
22.62 21.52 21.48 22.33 21.66 21.36 
23.69 23.98 23.71 22.35 
23.8 21.24 21.59 21.87 22.43 23.39 
Total 
Cross 
Section 
Area 
Damaged 
Cross 
Section 
Area 1 
Damaged 
Cross 
Section 
Area 2 
84.84 80.43 81.7 82.83 81.49 81.37 
4.5 4.25 3.47 
5.41 6.75 5.2 7.13 5.87 5.13 
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TABLE 3-continued 
Dermorphin H Treated 
Damaged 6.43 7.34 4.82 6.77 6.22 5.36 
Cross 
Section 
Area 3 
Damaged 
Cross 
Section 
Area 4 
3.45 4.15 
Total 
Damaged 
Cross 
Section 
Area 
Damaged % 
Corrected 
Volume 
19.79 22.56 17.15 22.77 20.23 17.85 
23.33 
39.58 
28.05 
45.12 
20.99 
34.3 
27.49 
45.54 
24. 83 
40.46 
21.94 
35.7 
For animals receiving Dermorphin H after one hour of 
ischemia, the infarct volume was reduced to about 24% 
(total damaged cross section area of 120.35, total cross 
section are of 492.66, 120.35/492.66:0.244. In all six Der 
morphin H treated animals, the corrected volume was 240.7, 
yielding an infarct volume of 40.12 mm3 (2407/ 6), with a 
standard deviation of 4.652. 
These results are summarized as follows. 
Average Infarct Standard Infarct 
Treatment Volume (mm3) Deviation Volume 
Control 71.35 8.598 42% 
Deltorphin A 49.99 10.63 30% 
Dermorphin H 40.12 4.652 24% 
The data demonstrate the ef?cacy of Deltorphin A and 
Dermorphin H treatment post cerebral ischemia. 
Pretreatment with Deltorphin A SEQ ID N011 and Der 
morphin H SEQ ID N012 also signi?cantly decreased the 
cardiac form of troponin I (cTn-l) values following 20 min 
ischemia, as shown in FIG. 2. An increase in cTn-l, a protein 
associated speci?cally with the cardiac muscle, indicates 
myocardial damage, likewise, a decrease in cTn-l indicates 
less cardiac damage. 
FIG. 3 is a histogram showing cTn-l released during 
reperfusion of isolated hearts after 20 min ischemia in rats 
treated 24 h prior to ischemia with 0.5 ml saline (control), 
2.0 mg/kg Deltorphin A SEQ ID N011, and 2.0 ml/kg 
Dermorphin H SEQ ID N012. The solid bars represent 
control animals (n:6), the open bars represent DeltorphinA 
SEQ ID N011 treated animals (n:6), and the hatched bars 
represent Dermorphin H SEQ ID N012 treated animals 
(n:6). At time points during reperfusion where samples 
were collected for cTn-l analysis (1, 60, and 120 min 
reperfusion), Tn-l levels in control rats were signi?cantly 
higher than Tn-l levels in Deltorphin A SEQ ID N011 
treated rats at 1 min and 60 minutes following reperfusion, 
and were also higher at 120 min following reperfusion. Tn-l 
levels in control rats were higher than Tn-l levels in 
Dermorphin H SEQ ID N012 treated rats at 1 minute and 
120 minutes following reperfusion. This data indicated that 
pretreatment with Deltorphin A SEQ ID N011 and Dermor 
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phin H SEQ ID N012 decreased the damage to the myocar 
dium, as compared to untreated animals. 
Deltorphin A SEQ ID N011 and Dermorphin H SEQ ID 
N012 pretreatment also resulted in improved postischemic 
ventricular function. FIG. 3 is a graph of end diastolic 
pressure in mm/Hg in the left ventricle (LVEDP) during 
reperfusion of isolated rat hearts after 20 min ischemia in 
rats pretreated 24 h prior to ischemia with 2.0 mg/kg 
Deltorphin A SEQ ID N011 or 2.0 mg/kg Dermorphin H 
SEQ ID N012. 0pen squares are from treated animals, and 
solid circles are from animals treated with 0.5 ml saline 
(control). FIG. 4 is a graph showing percent of functional 
recovery during reperfusion of isolated rat hearts after 20 
min ischemia in rats treated 24 h prior to ischemia with 2.0 
mg/kg DeltorphinA SEQ ID N011 or 2.0 mg/kg Dermorphin 
H SEQ ID N012. 0pen squares are from treated animals, and 
solid circles are from control animals. Differences in recov 
ery of developed pressure (DP) in hearts from Deltorphin A 
SEQ ID N011 and Dermorphin H SEQ ID N012 treated 
animals remained lower following the initiation of reperfu 
sion, as shown in FIG. 3. As shown in FIG. 4, left ventricular 
functional recovery (% recovery of baseline preischemic 
developed pressure during reperfusion) for animals treated 
with 2 mg/kg Deltorphin A SEQ ID N011 was signi?cantly 
increased over control animals up to 120 min following 
reperfusion (p:0.01). Left ventricular functional recovery 
for animals treated with Dermorphin-H SEQ ID N012 (2.0 
mg/kg) was also increased over control animals up to 120 
min post reperfusion, but the increase was not statistically 
signi?cant. 
As shown in FIG. 5, left ventricular functional recovery 
was signi?cantly improved in Deltorphin A SEQ ID N011 
treated animals (about 85%) (open bar) compared to control 
animals (about 51%) (solid bar) at 5 min of reperfusion, 
while left ventricular functional recovery in Dermorphin H 
SEQ ID N012 treated animals and control animals was about 
the same (about 51%). 
These results show that in a normoxic, isolated perfused 
rat heart preparation, administration of Deltorphin A SEQ ID 
N011 and Dermorphin H SEQ ID N012 confers cardiopro 
tection when administered either prior to planned ischemia 
or post ischemia. The salutary effects on the post-ischemic 
myocardium include reduced infarct siZe, reduced infarct 
volume, decreased release of cardiospeci?c troponin I, and 
improved ventricular performance. 
As another bene?t, Deltorphin A SEQ ID N011 and 
Dermorphin H SEQ ID N012 may provide a bene?t in 
protecting against arrhythmias, similar to the effect of the 
o-opioid receptor agonist TAN-67, as reported by Fryer et al. 
in 274 J. Biol. Chem. 451*457, 2000, which is expressly 
incorporated by reference herein in its entirety. 
The invention in its broader aspects is therefore not 
limited to the speci?c details, representative apparatus and 
method, and illustrative examples shown and described. 
Accordingly, departures may be made from such details 
without departing from the spirit or scope of applicant’s 
general inventive concept. 
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SEQUENCE LISTING 
NUMBER OF SEQ ID NOS: 2 
SEQ ID NO 1 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
NAME/KEY: MODQRES 
LOCATION: (1)...(7) 
OTHER INFORMATION: Xaa = D-Met; artificial sequence is completely 
synthesized 
SEQUENCE: 1 
Tyr Xaa Phe His Leu Met Asp 
l 5 
SEQ ID NO 2 
LENGTH: 13 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
NAME/KEY: MODiRES 
LOCATION: (1)...(13) 
OTHER INFORMATION: Xaa = D-Ala; artificial sequence is completely 
synthesized 
SEQUENCE: 2 
Tyr Xaa Phe Gly Tyr Pro Ser Gly Glu Ala Lys Lys Ile 
l 5 10 
What is claimed is: pharmaceutically acceptable formulation, Wherein said com 
1. A composition comprising a compound that affects 35 pound that affects NO synthase is arginine hydrochloride. 
nitrogen oxide (NO synthase) and at least one of Deltorphin 
A, SEQ ID No: l, or Dermorphin H, SEQ ID No: 2, in a * * * * * 
